Engineered liposomes for potential α-particle therapy of metastatic cancer

Journal of Nuclear Medicine

Volumn 45, Issue 2, 2004, Pages 253-260

  Sofou, Stavroula ^a   Thomas, James L ^b   Lin, Hung Yin ^b   McDevitt, Michael R ^a   Scheinberg, David A ^a   Sgouros, George ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Columbia University ^*  (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

particle therapy; 225Ac; 225Ac membrane binding; Liposomes

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ACTINIUM; AMPHOLYTE; BISMUTH; LIPOSOME; PHOSPHATIDYLCHOLINE; RADIOISOTOPE;

ALPHA RADIATION; ARTICLE; MEMBRANE BINDING; METASTASIS; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; ELECTRON MICROSCOPY; HUMAN;

ACTINIUM; ALPHA PARTICLES; ANIMALS; BISMUTH; HUMANS; LIPOSOMES; MICROSCOPY, ELECTRON; NEOPLASM METASTASIS; RADIOISOTOPES;

EID: 1542609207     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Humm JL. A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. Int J Radiat Oncol Biol Phys. 1987;13:1767-1773.
2. Humm JL, Chin LM. A model of cell inactivation by alpha-particle internal emitters. Radiat Res. 1993;134:143-150.
3. Macklis RM, Kinsey BM, Kassis AI, et al. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science. 1988;240:1024-1026.
4. Zalutsky MR, Cokgor I, Akabani G, et al. Phase I trial of alpha-particle-emitting astatine-211 labeled chimeric anti-tenascin antibody in recurrent malignant glioma patients [abstract]. Proc Am Assoc Cancer Res. 2000;41:544.
5. Jurcic JG, McDevitt MR, Sgouros G, et al. Targeted alpha-particle therapy for myeloid leukemias: a phase I trial of bismuth-213-HuM195 (anti-CD33) [abstract]. Blood. 1997;90:(suppl 1)504a.
6. 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med. 1999;40:1935-1946.
7. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha-particle immunotherapy for myeloid leukemia. Blood. 2002;100:1233-1239.
8. 90Y-labeled CO17-1A Fab′ fragments in a human colonic cancer model. Cancer Res. 1999;59:2635-2643.
9. Behr TM, Sgouros G, Stabin MG, et al. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters. Clin Cancer Res. 1999;5:3031s-3043s.
10. 213Bi: an alpha-particle emitter. Nucl Med Biol. 1998;25:241-246.
11. Zalutsky MR, McLendon RE, Garg PK, Archer GE, Schuster JM, Bigner DD. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. Cancer Res. 1994;54:4719-4725.
12. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537-1540.
13. Zhang M, Zhang Z, Garmestani K, et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci USA. 2003;100:1891-1895.
14. Cullis PR, DeKruijff B. Lipid polymorphism and the functional role of lipids in biological membranes. Biochim Biophys Acta. 1979;559:399-420.
15. Lasic DD. Novel applications of liposomes. Trends Biotechnol. 1998;16:307-321.
16. Drummond DD, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51:691-743.
17. Huang SK, Martin FJ, Jay G, Vogel J, Papahadjopoulos D, Friend DS. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am J Pathol. 1993;143:10-14.
18. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW. Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res. 1993;53:3765-3770.
19. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994;54:3352-3356.
20. Boerman OC, Storm G, Oyen WJG. Sterically stabilized liposomes labelled with In-111 to image focal infection in rats. J Nucl Med. 1995;36:1639-1644.
21. Emfietzoglou D, Kostarelos K, Sgouros G. An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy. J Nucl Med. 2001;42:499-504.
22. Kennel SJ, Brechbiel MW, Milenic DE, Schlom J, Mirzadeh S. Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49. Cancer Biother Radiopharm. 2002;17:219-231.
23. Kennel SJ, Chappell LL, Dadachova K, et al. Evaluation of Ac-225 for vascular targeted radioimmunotherapy of lung tumors. Cancer Biother Biopharm. 2000;15:235-244.
24. Cevc G, Marsh D. Phospholipid Bilayers: Physical Principles and Models. New York, NY: Wiley; 1987:190-193.
25. Castile JD, Taylor KMG. Factors affecting the size distribution of liposomes produced by freeze-thaw extrusion. Int J Pharm. 1999;188:87-95.
26. Stensrud G, Redford K, Smistad G, Karlsen J. Effects of gamma irradiation on solid and lyophilised phospholipids. Rad Phys Chem. 1999;56:611-622.
27. McIntyre JC, Sleight RG. Fluorescence assay for phospholipid membrane asymmetry. Biochemistry. 1991;30:11819-11827.
28. Provencher SW. A constrained regularization method for inverting data represented by linear algebraic or integral equations. Comput Phys Commun. 1982;27:213-227.
29. Teraoka I. Polymer Solutions: An Introduction to Physical Properties. New York, NY: John Wiley & Sons; 2002:188-191.
30. Ziegler J. The Stopping and Range of Ions in Matter [SRIM Web site]. Available at: http://www.srim.org. Accessed Nov. 18, 2003.
31. Sgouros S. Long-lived alpha emitters in radioimmunotherapy: the mischievous progeny. Cancer Biother Biopharm. 2000;15:219-221.
32. Cevc G. The molecular mechanism of interaction between monovalent ions and polar surfaces, such as lipid bilayer membranes. Chem Phys Letters. 1990;170:283-288.
33. Binder H, Zschoernig O. The effect of metal cations on the phase behavior and hydration characteristics of phospholipid membranes. Chem Phys Lipids. 2002;115:39-61.
34. Rippe B, Rosengren BI, Venturoli D. The peritoneal microcirculation in peritoneal dialysis. Microcirculation. 2001;8:303-320.
35. Ahl PL, Bhatia SK, Meers P, et al. Enhancement of the in vivo circulation lifetime of L-a-distearoylphosphatidylcholine liposomes: importance of liposomal aggregation versus complement opsonization. Biochim Biophys Acta. 1997;1329:370-382.
36. Park JW, Kirpotin DB, Hong K, et al. Tumor targeting using anti-her2 immunoliposomes. J Control Release. 2001;74:95-113.